| Patient | Mumtaz Mahal |
|---|---|
| Date of birth | 1988-04-27 |
| Identifiers | MRN HR-RE006-SYN; SSN (made up) 000-06-7184 |
| Document date | 2026-03-03 |
| Author | Farzana Qureshi-Lindholm, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 21 weeks with the anatomy scan. [S]
Mumtaz Mahal returns at 21 weeks 2 days, four weeks after her first intravenous iron dose, which she tolerated without reaction. She has more energy and is less breathless. It is the month of Ramadan; she has chosen not to fast during the pregnancy, as her faith allows, and plans to make up the days later. She feels the baby move every day. She takes aspirin and folic acid. She has no headache, visual change, abdominal pain, contractions, bleeding, or urinary symptoms. She had the anatomy scan this morning. [S]
| Element | Detail |
|---|---|
| Iron | First intravenous dose four weeks ago, no reaction; more energy |
| Fasting | Not fasting this Ramadan, by her own choice |
| Fetal movement | Daily |
| Scan | Anatomy scan this morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better |
| Cardiovascular | Negative | Breathless only on several flights of stairs |
| Gastrointestinal | Negative | Nausea and constipation gone since stopping oral iron |
| Genitourinary | Negative | No bleeding, leaking fluid, or urinary symptoms |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-06 | active | S |
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day | One tablet every other morning with water or orange juice, apart from tea and calcium | Oral route | 2026-01-06 to 2026-02-03 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 2026-01-06 | active | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 2026-02-03 to 2026-02-03 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 2026-03-03 to 2026-03-03 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 157 | cm | S |
| 2026-03-03 | Body weight | 61.9 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 25.1 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 88 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.7 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 10.5-15 g/dL | Normal | S |
| 2026-03-03 | Ferritin [Mass/volume] in Serum or Plasma | 96 | ng/mL | 30-150 ng/mL | Normal | S |
| 2026-03-03 | Fetal Body weight estimated by US | 410 | g | About the 50th centile for 21 weeks | Normal | S |
Vital signs recorded on 2026-03-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; better color |
| Abdomen | Fundal height 21 cm; non-tender |
| Fetal | Scan: normal anatomy, estimated weight 410 g; fetal heart 148 per minute |
| Placenta | Posterior and fundal, lower edge more than 5 cm from the internal os; no lacunae; normal retroplacental clear zone |
| Urine dipstick | Protein negative |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12 | active | confirmed | O09.529 | S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic. |
| Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living children | active | confirmed | O09.40 | S — Synthetic modern problem anchored to her documented thirteen earlier births. |
| Short interpregnancy interval: conception about five and a half months after her last birth | active | confirmed | O09.899 | S — Synthetic modern problem anchored to the documented fourteen months between her last two births. |
| Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mL | active | confirmed | O99.019 | S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 104/62 mmHg; urine protein negative |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 148 per minute; fundal height 21 cm |
| Examination | Weight gain | Every prenatal visit | Completed today | 61.9 kg, up 3.3 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 10.9 g/dL and ferritin 96 ng/mL after the first intravenous dose; second dose today |
| Medication safety | Intravenous iron infusion safety | With each infusion | Completed today | No reaction to the first dose; second dose given with 30 minutes of observation, no reaction |
| Imaging | Detailed anatomy scan with placental location | At 18 to 22 weeks | Completed today | Normal anatomy; estimated weight 410 g; placenta posterior fundal, clear of the os; no signs of accreta |
| Imaging | Repeat placental scan at 32 weeks | Only if the placenta is low-lying or covers the os | Not indicated | Placenta well clear of the os |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly; no bruising or bleeding |
| Laboratory | Gestational diabetes screen | At 24 to 28 weeks | Due | Glucose challenge booked for 27 weeks |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Due | Second-trimester screen at 27 weeks |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Up to date | No placenta previa or accreta; risk factors remain grand multiparity and anemia, now improving |
Goal progress:
Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); Obstetric Care Consensus No. 7: Placenta Accreta Spectrum (2018)
Follow-up: Prenatal visit at 27 weeks with the glucose challenge, blood count, and Tdap. Next scheduled visit 2026-04-14: prenatal visit at 27 weeks: glucose challenge, blood count, and Tdap. [S]